Home >> Research Area >>Microbiology and Virology>>Antibiotic>> Gatifloxacin mesylate

Gatifloxacin mesylate

CAS# 316819-28-0

Gatifloxacin mesylate

Catalog No. BCC4225----Order now to get a substantial discount!

Product Name & Size Price Stock
Gatifloxacin mesylate: 5mg $17 In Stock
Gatifloxacin mesylate: 10mg Please Inquire In Stock
Gatifloxacin mesylate: 20mg Please Inquire Please Inquire
Gatifloxacin mesylate: 50mg Please Inquire Please Inquire
Gatifloxacin mesylate: 100mg Please Inquire Please Inquire
Gatifloxacin mesylate: 200mg Please Inquire Please Inquire
Gatifloxacin mesylate: 500mg Please Inquire Please Inquire
Gatifloxacin mesylate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Gatifloxacin mesylate

Number of papers citing our products

Chemical structure

Gatifloxacin mesylate

3D structure

Chemical Properties of Gatifloxacin mesylate

Cas No. 316819-28-0 SDF Download SDF
PubChem ID 16040196 Appearance Powder
Formula C20H26FN3O7S M.Wt 471.5
Type of Compound N/A Storage Desiccate at -20°C
Synonyms AM 1155 mesylate; BMS 206584-01 mesylate; PD 135432 mesylate
Solubility Soluble in DMSO
Chemical Name 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid
SMILES CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F.CS(=O)(=O)O
Standard InChIKey PMMNVFFMFJMFDB-UHFFFAOYSA-N
Standard InChI InChI=1S/C19H22FN3O4.CH4O3S/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26;1-5(2,3)4/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26);1H3,(H,2,3,4)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Gatifloxacin mesylate

DescriptionGatifloxacin (mesylate) is an antibiotic of the fourth-generation fluoroquinolone family, it inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Target: Antibacterial Gatifloxacin (mesylate) is the mesylate salt of Gatifloxacin which is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Gatifloxacin had activity equal to that of tosufloxacin and activity more potent than those of norfloxacin, ofloxacin, ciprofloxacin, and sparfloxacin against the second-step mutants (grlA gyrA; gatifloxacin MIC range, 1.56 to 3.13 microg/ml) and had the most potent activity against the third-step mutants (grlA gyrA grlA; gatifloxacin MIC range, 1.56 to 6.25 microg/ml), suggesting that gatifloxacin possesses the most potent inhibitory activity against singly mutated topo IV and singly mutated DNA gyrase among the quinolones tested [1]. Ophthalmic gatifloxacin 0.3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin. Trends favored gatifloxacin in fluorescein retention scores [2]. Clinical indications: Bacterial infection Toxicity: Hepatotoxicity; Acute pancreatitis [3]; Torsades de pointes [4]

References:
[1]. Fukuda, H., S. Hori, and K. Hiramatsu, Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. A [2]. Jensen, H., et al., Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. J Ocul Pharmacol Ther, 2005. 21(1): p. 36-43. [3]. Cheung, O., et al., Gatifloxacin-induced hepatotoxicity and acute pancreatitis. Ann Intern Med, 2004. 140(1): p. 73-4. [4]. Fteha, A., et al., Gatifloxacin induced torsades de pointes. Pacing Clin Electrophysiol, 2004. 27(10): p. 1449-50.

Gatifloxacin mesylate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Gatifloxacin mesylate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Gatifloxacin mesylate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1209 mL 10.6045 mL 21.2089 mL 42.4178 mL 53.0223 mL
5 mM 0.4242 mL 2.1209 mL 4.2418 mL 8.4836 mL 10.6045 mL
10 mM 0.2121 mL 1.0604 mL 2.1209 mL 4.2418 mL 5.3022 mL
50 mM 0.0424 mL 0.2121 mL 0.4242 mL 0.8484 mL 1.0604 mL
100 mM 0.0212 mL 0.106 mL 0.2121 mL 0.4242 mL 0.5302 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Gatifloxacin mesylate

Gatifloxacin (mesylate) is an antibiotic of the fourth-generation fluoroquinolone family, it inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.

Featured Products
New Products
 

References on Gatifloxacin mesylate

Comprehensive evaluation of formulation factors for ocular penetration of fluoroquinolones in rabbits using cassette dosing technique.[Pubmed:26955263]

Drug Des Devel Ther. 2016 Feb 22;10:811-23.

OBJECTIVE: Corneal permeability of drugs is an important factor used to assess the efficacy of topical preparations. Transcorneal penetration of drugs from aqueous formulation is governed by various physiological, physiochemical, and formulation factors. In the present study, we investigated the effect of formulation factors like concentration, pH, and volume of instillation across the cornea using cassette dosing technique for ophthalmic fluoroquinolones (FQs). MATERIALS AND METHODS: Sterile cocktail formulations were prepared using four congeneric ophthalmic FQs (ofloxacin, sparfloxacin, pefloxacin mesylate, and gatifloxacin) at concentrations of 0.025%, 0.5%, and 0.1%. Each formulation was adjusted to different pH ranges (4.5, 7.0, and 8.0) and assessed for transcorneal penetration in vivo in rabbit's cornea (n=4 eyes) at three different volumes (12.5, 25, and 50 muL). Aqueous humor was aspirated through paracentesis after applying local anesthesia at 0, 5, 15, 30, 60, 120, and 240 minutes postdosing. The biosamples collected from a total of 27 groups were analyzed using liquid chromatography-tandem mass spectroscopy to determine transcorneal permeability of all four FQs individually. RESULTS: Increase in concentration showed an increase in penetration up to 0.05%; thereafter, the effect of concentration was found to be dependent on volume of instillation as we observed a decrease in transcorneal penetration. The highest transcorneal penetration of all FQs was observed at pH 7.0 at concentration 0.05% followed by 0.025% at pH 4.5. Lastly, increasing the volume of instillation from 12.5 to 50 muL showed a significant fall in transcorneal penetration. CONCLUSION: The study concludes that formulation factors showed discernible effect on transcorneal permeation; therefore, due emphasis should be given on drug development and design of ophthalmic formulation.

Description

Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.

Keywords:

Gatifloxacin mesylate,316819-28-0,AM 1155 mesylate; BMS 206584-01 mesylate; PD 135432 mesylate,Natural Products,Antibiotic, buy Gatifloxacin mesylate , Gatifloxacin mesylate supplier , purchase Gatifloxacin mesylate , Gatifloxacin mesylate cost , Gatifloxacin mesylate manufacturer , order Gatifloxacin mesylate , high purity Gatifloxacin mesylate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: